Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
$MYOV Myovant Sciences shares are rallied over 8% reaching highs of $26.78 after the company got FDA approval of Orgovyx for the treatment of advanced prostate cancer.
Consumer finance firm, CURO Group’s (NYSE: CURO) share price has skyrocketed after it said on Friday that the company is set to benefit from Katapult’s announced merger with SPAC, FinServ Acquisition Corp (NASDAQ: FSRV)
CURO: +127.93% $20.03
Mereo BioPharma (NASDAQ: MREO, AIM: MPH) shares are rallying premarket on Friday after the company announced a license and collaboration agreement with Ultragenyx Pharmaceutical (NASDAQ: RARE) for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).
Mereo BioPharma: +47.06% $3.25
Palantir Technologies (NYSE: PLTR) shares are trading 3.67% lower at $26.23 after Credit Suisse downgraded the stock from Neutral to Underperform and announced a $17 price target.
Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.
Shares of biotechnology company Synairgen (LON: SNG) are rallying on Friday after the company provided an update on its Phase 3 trial evaluating SNG001 as a treatment for Covid-19.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .